Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

C4 Therapeutics (CCCC) EBIAT (2019 - 2026)

C4 Therapeutics has reported EBIAT over the past 8 years, most recently at -$25.1 million for Q1 2026.

  • For Q1 2026, EBIAT rose 4.53% year-over-year to -$25.1 million; the TTM value through Mar 2026 reached -$103.8 million, down 0.51%, while the annual FY2025 figure was -$105.0 million, 0.3% changed from the prior year.
  • EBIAT for Q1 2026 was -$25.1 million at C4 Therapeutics, down from -$20.5 million in the prior quarter.
  • Over five years, EBIAT peaked at -$17.7 million in Q2 2024 and troughed at -$37.2 million in Q4 2022.
  • A 5-year average of -$29.2 million and a median of -$28.4 million in 2024 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 137.36% in 2022 and later soared 50.68% in 2024.
  • Year by year, EBIAT stood at -$37.2 million in 2022, then rose by 6.54% to -$34.8 million in 2023, then grew by 0.52% to -$34.6 million in 2024, then surged by 40.73% to -$20.5 million in 2025, then fell by 22.63% to -$25.1 million in 2026.
  • Business Quant data shows EBIAT for CCCC at -$25.1 million in Q1 2026, -$20.5 million in Q4 2025, and -$32.2 million in Q3 2025.